Ocrelizumab: A Deep Dive into IDC-2403's Mechanism Ocrelizumab, initially investigated as IDC-2403, exhibits a unique pathway of action targeting be cells, key in the manifestation of several sclerosis and related conditions . It primarily binds to the CD20 protein expressed on most mature be cells, leading to their elimination via antibody-depend